Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease

Fig. 3

Clinical parameters, anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers, neutralizing effects and infusion associated reactions (IARs) for patients with an intermediate (patient 6–20) or low (patient 21 and 22) peak antibody titer. Each graph represents an individual patient. For each patient, anti-rhGAA antibody titers are shown on the left Y-axis. The occurrence of IARs is displayed (exclamation marks). Clinical outcome parameters, the Medical Research Council (MRC) sum score (expressed as a percentage of maximal muscle strength), Forced Vital Capacity (FVC) in upright position (expressed as a percentage of predicted normal values) and Quick Motor Function Test (QMFT) sum score (expressed as a percentage of the maximal score) are shown on the right Y-axis

Back to article page